UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

GSK3 and tau: two convergence points in Alzheimer's disease

Journal of Alzheimer's disease, 2013-01, Vol.33 Suppl 1 (s1), p.S141-S144

2013

Volltextzugriff (PDF)

NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy

The Journal of clinical investigation, 2010-07, Vol.120 (7), p.2432-2445

2010

Volltextzugriff (PDF)

Full Reversal of Alzheimer's Disease-Like Phenotype in a Mouse Model with Conditional Overexpression of Glycogen Synthase Kinase-3

The Journal of neuroscience, 2006-05, Vol.26 (19), p.5083-5090

2006

Volltextzugriff (PDF)

Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome

Neurobiology of disease, 2019-07, Vol.127, p.210-222

2019

Volltextzugriff (PDF)

N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation

The Journal of biological chemistry, 2007-08, Vol.282 (31), p.22406-22413

2007

Volltextzugriff (PDF)

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

Brain (London, England : 1878), 2011-01, Vol.134 (Pt 1), p.119-136

2011

Volltextzugriff (PDF)

Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418

The Journal of biological chemistry, 2003-11, Vol.278 (46), p.45937-45945

2003

Volltextzugriff (PDF)

Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome

Brain pathology (Zurich, Switzerland), 2016-09, Vol.26 (5), p.593-605

2016

Volltextzugriff (PDF)

Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent

PloS one, 2013-08, Vol.8 (8), p.e70952-e70952

2013

Volltextzugriff (PDF)

Impaired ATF6α processing, decreased Rheb and neuronal cell cycle re-entry in Huntington's disease

Neurobiology of disease, 2011-01, Vol.41 (1), p.23-32

2011

Volltextzugriff (PDF)

GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration

Frontiers in molecular neuroscience, 2011-01, Vol.4, p.45

2011

Volltextzugriff (PDF)

CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington's disease

Acta neuropathologica communications, 2022-06, Vol.10 (1), p.83-83, Article 83

2022

Volltextzugriff (PDF)

α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease

Human molecular genetics, 2012-02, Vol.21 (3), p.495-510

2012

Volltextzugriff (PDF)

Accumulation of Ubiquitin Conjugates in a Polyglutamine Disease Model Occurs without Global Ubiquitin/Proteasome System Impairment

Proceedings of the National Academy of Sciences - PNAS, 2009-08, Vol.106 (33), p.13986-13991

2009

Volltextzugriff (PDF)

Huntington's disease is a four-repeat tauopathy with tau nuclear rods

Nature medicine, 2014-08, Vol.20 (8), p.881-885

2014

Volltextzugriff (PDF)

Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration

Neurobiology of aging, 2006-09, Vol.27 (9), p.1258-1268

2006

Volltextzugriff (PDF)

GSK3: A possible link between beta amyloid peptide and tau protein

Experimental neurology, 2010-06, Vol.223 (2), p.322-325

2010

Volltextzugriff (PDF)

Correction to: CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease

Acta neuropathologica communications, 2022-06, Vol.10 (1), p.1-89, Article 89

2022

Volltextzugriff (PDF)

Tau phosphorylation in hippocampus results in toxic gain-of-function

Biochemical Society transactions, 2010-08, Vol.38 (4), p.977-980

2010

Volltextzugriff (PDF)

Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration

The FASEB journal, 2009-06, Vol.23 (6), p.1893-1906

2009

Volltextzugriff (PDF)

Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing

Nature (London), 2018-08, Vol.560 (7719), p.441-446

2018

Volltextzugriff (PDF)

Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin–proteasome system

Acta neuropathologica, 2016-03, Vol.131 (3), p.411-425

2016

Volltextzugriff (PDF)

Ubiquitin-proteasome system involvement in Huntington's disease

Frontiers in molecular neuroscience, 2014, Vol.7, p.77-77

2014

Volltextzugriff (PDF)

Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease

Frontiers in cellular neuroscience, 2020-01, Vol.13, p.574-574

2020

Volltextzugriff (PDF)

Looking for novel functions of tau

Biochemical Society transactions, 2012-08, Vol.40 (4), p.653-655

2012

Volltextzugriff (PDF)

1 – 25 von 1.965

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.696)
Mit Volltextzugriff
(1.764)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

GSK3 and tau: two convergence points in Alzheimer's disease

NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy

Full Reversal of Alzheimer's Disease-Like Phenotype in a Mouse Model with Conditional Overexpression of Glycogen Synthase Kinase-3

Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome

N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418

Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome

Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent

Impaired ATF6α processing, decreased Rheb and neuronal cell cycle re-entry in Huntington's disease

GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration

CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington's disease

α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease

Accumulation of Ubiquitin Conjugates in a Polyglutamine Disease Model Occurs without Global Ubiquitin/Proteasome System Impairment

Huntington's disease is a four-repeat tauopathy with tau nuclear rods

Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration

GSK3: A possible link between beta amyloid peptide and tau protein

Correction to: CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease

Tau phosphorylation in hippocampus results in toxic gain-of-function

Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration

Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing

Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin–proteasome system

Ubiquitin-proteasome system involvement in Huntington's disease

Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease

Looking for novel functions of tau

Suchergebnisse filtern